In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BioNano Genomics (BNGO – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $1.38.
According to TipRanks, McCarthy is an analyst with an average return of -34.1% and a 15.58% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, BioNano Genomics, and Inmune Bio.
Currently, the analyst consensus on BioNano Genomics is a Strong Buy with an average price target of $5.63.
See Insiders’ Hot Stocks on TipRanks >>
BNGO market cap is currently $403.8M and has a P/E ratio of -3.37.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.
Read More on BNGO:
- Bionano Genomics announces publication of results from OGM trial
- Bionano Genomics options imply 13.9% move in share price post-earnings
- Bionano Genomics obtains class I registrations from China’s NMPA
- Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies
- Bionano Shares Overview of AGBT Pre-Conference Workshop Program Along with Details of Company’s Innovative Research Grant Opportunity
